NCT07174310: A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
- State
- Under way
- Phase
- Phase 3
- People
- 900 planned
- Started
- 24 Nov 2025
- Primary completion
- 30 Jun 2029
- Arms
- Placebo
- Results
- None posted
- Papers
- doi:10.1016/s0140-6736(26)00865-2
- 15 Sep 2025: Trial registered
- 24 Nov 2025: Trial started